How to Finance a Podiatry Practice Acquisition

From SBA 7(a) loans to seller earnouts, understand the capital structures that work for $1M–$5M podiatry practice deals and what lenders actually want to see.

Find Podiatry Practice Deals SBA Calculator →

Podiatry practices are among the most SBA-financeable healthcare businesses due to stable Medicare reimbursement, recurring diabetic and chronic care volume, and predictable EBITDA margins of 15–30%. Buyers typically combine SBA debt, seller notes, and equity to close deals at 3x–5.5x EBITDA. Lenders scrutinize payer mix concentration, physician transition risk, and accounts receivable quality when underwriting these acquisitions.

Financing Options for Podiatry Practice Acquisitions

SBA 7(a) Loan

$500K–$5MPrime + 2.75%–3.75% (currently ~10.5%–11.5% variable)

The most common financing vehicle for podiatry practice acquisitions. Covers goodwill, equipment, and working capital with up to 90% LTV, requiring 10–15% buyer equity injection and strong personal credit.

Pros

Low equity requirement of 10–15% allows buyers to preserve capital for post-close operations and staffing investments
10-year term on practice acquisitions reduces monthly debt service burden compared to conventional loans
Goodwill financing accepted, which is critical since podiatry practice value is largely intangible patient relationships

Cons

×Personal guarantee required, putting buyer's personal assets at risk if the practice underperforms post-acquisition
×SBA lenders will scrutinize Medicare concentration above 60%, potentially limiting loan approval for high-Medicare practices
×Lengthy approval timeline of 60–90 days can complicate deal timing when sellers have competing offers

Seller Financing / Seller Note

$100K–$600K (5–20% of purchase price)6%–8% fixed, interest-only or deferred during physician transition period

The selling podiatrist carries 5–20% of the purchase price as a subordinated note, often paired with an employment or transition agreement. Signals seller confidence and bridges lender equity gaps.

Pros

Reduces buyer equity injection requirement and signals the seller has confidence in the practice's post-sale performance
Aligns seller incentives with a smooth patient and staff transition, reducing physician departure risk
SBA lenders typically allow seller notes on standby, improving total deal structure flexibility

Cons

×Seller may resist subordinated note if they need full liquidity at close, common in retirement-driven exits
×Default on seller note can damage physician relationship during the critical post-acquisition transition period
×Note terms must be carefully documented to avoid Stark Law or anti-kickback issues in healthcare transactions

Equity Recapitalization / DSO Platform Investment

$1M–$5M+ depending on platform EBITDA targets and roll-up strategyNot applicable — equity structure; IRR targets of 20–30% for PE sponsors

A private equity-backed specialty group or podiatry DSO acquires a majority stake while the selling physician retains 20–30% equity, rolling into the platform for a future liquidity event.

Pros

Seller achieves partial liquidity today while retaining upside in a growing multi-site podiatry platform
Eliminates financing contingency risk since PE platforms typically close with committed capital without SBA approval delays
Buyer gains operational infrastructure, billing systems, and referral network support from the sponsoring platform

Cons

×Selling physician surrenders majority control, which can conflict with clinical autonomy and practice culture preferences
×Complex legal structure requires healthcare M&A attorneys familiar with corporate practice of medicine and Stark Law compliance
×Rolled equity is illiquid until a platform exit event, which may be 4–7 years away with no guaranteed return

Sample Capital Stack

$2,200,000 (based on $550K EBITDA at 4x multiple for established podiatry practice)

Purchase Price

~$22,500/month combined debt service on SBA loan and seller note at current rates over 10-year term

Monthly Service

Approximately 1.45x DSCR based on $550K EBITDA, comfortably above the 1.25x minimum most SBA healthcare lenders require

DSCR

SBA 7(a) loan: $1,760,000 (80%) | Seller note on standby: $220,000 (10%) | Buyer equity injection: $220,000 (10%)

Model your own deal structure →

Lender Tips for Podiatry Practice Acquisitions

1Prepare a payer mix breakdown showing Medicare below 60% of total collections — lenders treating diabetic foot care portfolios will want to see commercial and private pay offsetting Medicare dependency.
2Document physician transition plan and associate coverage clearly in your loan package; lenders view single-physician revenue concentration as the top default risk in podiatry practice acquisitions.
3Clean accounts receivable aging reports and a recent billing compliance audit will accelerate underwriting — unresolved Medicare overpayment demands or high claim denial rates are automatic red flags.
4Engage an SBA lender with dedicated healthcare practice lending experience; generalist SBA lenders often misunderstand goodwill valuation and Stark Law compliance structures unique to podiatry deals.

Frequently Asked Questions

Can I use an SBA loan to buy a podiatry practice where the seller is retiring and leaving post-close?

Yes, but lenders will require evidence of associate podiatrists or mid-level providers maintaining revenue continuity. A transition employment agreement of 6–12 months from the seller significantly improves approval odds.

What EBITDA margin do lenders expect before approving an SBA loan for a podiatry practice acquisition?

Most SBA lenders require a minimum 1.25x DSCR, implying EBITDA margins of roughly 20–25% after normalized owner compensation addbacks, which aligns with the 15–30% range typical of well-run podiatry practices.

How does Medicare payer mix concentration affect my ability to get acquisition financing?

Medicare above 60–65% of collections raises lender concerns about reimbursement rate risk. Buyers should document diabetic wound care and orthotics revenue streams, which carry stronger reimbursement stability, to offset concentration concerns.

Is a seller earnout the same as a seller note in a podiatry practice acquisition?

No. A seller note is a fixed debt obligation; an earnout is contingent on post-close performance metrics like patient retention or revenue targets. Deals often combine both, with the note secured and earnout tied to a 12–24 month transition period.

More Podiatry Practice Guides

Buy a Podiatry Practice Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Podiatry Practice acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required